AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

โ† Trials
๐Ÿงช

Heart Failure-USB: Prediction and Progression

Recruitingn/aAges 18 Years - anyAllUniversity Hospital, Basel, Switzerland
๐Ÿ’ฌ

In plain words

What the trial is, and whether it could suit you

This retrospective cohort study is to identify triggers of heart failure (HF) development and drivers of HF progression as well as the underlying cardiac disease (phenotype) to identify patients at risk and predict the clinical course of the disease. Data of patients who were hospitalized during the years 2010-2023 with acute coronary syndrome (ACS) and/ or with acute heart failure (AHF) will be collected and analyzed. In a subgroup cohort efficacy and safety of digoxin in patients with acute heart failure triggered by tachyarrhythmia will be evaluated.

Sign in to get the eligibility rules as simple questions to take to your doctor.

๐Ÿ“‹ Eligibility rules (as published)
Inclusion Criteria: * Patients hospitalized with a primary diagnosis of ACS * Patients hospitalized with a primary or secondary diagnosis of AHF Exclusion Criteria: * Existence of a documented statement of the patient against the scientific use of clinical data
๐Ÿ’Š

What it tests

  • medical chart review
  • data generated by direct IT export
๐Ÿ“

Where

1 site
Cardiology, University Hospital Basel
Basel, Switzerland
๐Ÿค Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible โ€” always decide together with your own doctor.
๐Ÿ›ก๏ธ

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it โ€” not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use ยท Privacy